NASDAQ:LEXX

Lexaria Bioscience Q4 2026 Earnings Date & Estimates

Lexaria Bioscience logo
$4.03 -0.46 (-10.24%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$4.09 +0.06 (+1.56%)
As of 11/20/2026 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lexaria Bioscience is estimated to report Q4 2026 earnings on Tuesday, November 24, 2026. The conference call is scheduled for 12:00 AM ET.

Upcoming Earnings Announcement

Quarter
Q4 2026
Announcement Date
Conference Call
12:00 AM ET

What Analysts Expect from Lexaria Bioscience in Q4 2026

Lexaria Bioscience is expected to post earnings of -$0.90 per share on revenue of $50 thousand. Lexaria Bioscience last reported on July 13, 2026, posting -$0.08 per share and missing the -$0.06 consensus estimate. Lexaria Bioscience has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.90
Expected Revenue
$50 thousand

Recent Track Record

Last Reported
Q3 2026
Last Quarter EPS
-$0.08 (Missed by -$0.02)
EPS Beat Rate
3 of last 8 quarters

Lexaria Bioscience Q4 2026 Earnings FAQ

Lexaria Bioscience (NASDAQ:LEXX) is estimated to report Q4 2026 earnings on Tuesday, November 24, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Lexaria Bioscience's Q4 2026 earnings conference call is scheduled for Tuesday, November 24, 2026 at 12:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Lexaria Bioscience to post earnings of -$0.90 per share for Q4 2026.

The consensus revenue estimate for Lexaria Bioscience is $50 thousand for Q4 2026.

Lexaria Bioscience Earnings Headlines

Lexaria Bioscience (LEXX) Projected to Release Earnings on Tuesday
Prediction: NVDA will “snap back” on this date
Others paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access for just $7. The specialized indicator shows when a stock is likely to "snap back," helping traders avoid buying at the peak. It can also flag when a stock may bounce off the bottom so you can time your entry. Run NVDA or any other popular AI stock through it before you place a trade.tc pixel
LEXX: Introducing DehydraTECH 3.0
Lexaria Bioscience advances 12% on Australian tax rebate
See More Lexaria Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lexaria Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexaria Bioscience and other key companies, straight to your email.

About Lexaria Bioscience

Lexaria Bioscience (NASDAQ:LEXX) is a biotechnology company developing DehydraTECH, a patented technology designed to improve the delivery and absorption of orally administered drugs and other active compounds. The platform incorporates active ingredients into a lipid-based formulation and is being studied for its potential to affect absorption and delivery characteristics.

The company’s research has explored applications in areas including hypertension, diabetes and weight management, epilepsy, and antiviral treatments. These programs are investigational; Lexaria’s work includes laboratory and clinical research rather than a broad portfolio of approved medicines.

Based in British Columbia, Canada, Lexaria focuses on developing and licensing its delivery technology and advancing research with pharmaceutical ingredients. The company has also developed consumer products in the past, including hemp-derived products, but its current activities center on DehydraTECH research and development.

View Lexaria Bioscience Profile